Submission Deadline
24 Jun 2021 (Vol 44 , Iss 03 )

Upcoming Publication
30 Jun 2021 (Vol 44 , Iss 03 )

Journal ID : TMJ-24-02-2021-10516
Download [This article belongs to Volume - 44, Issue - 02]
Total View : 322

Title : Screening of Carica papaya L. and Psidium guajava Leaves Fraction as Antiviral Drug to Dengue Virus

Abstract :

Up to now, there is no specific antiviral drug to dengue virus (DENV). Medicinal plants have been developing in order to combat DENV infection. The crude extract of Carica papaya L and Psidium guajava leaves showed antiviral activity to DENV in vitro. The aim of this study to screen antiviral activity to DENV among Carica papaya L and Psidium guajava leaves fractions. This research is a laboratory experimental study. The study was conducted at the Pharmacology laboratory, Faculty of Medicine, Sebelas Maret University and Virology and Molecular Biology Laboratory of the Department of Microbiology, Faculty of Medicine, The University of Indonesia. DENV at an MOI of 0.5 FFU/cell was treated with 20 ug/mL of Carica papaya L and Psidium guajava leaves fractions and was infected to Vero cell. The affectivity and safety of DENV antiviral drug was determined by focus assay and MTT assay respectively. Data from the subsequent research were processed using the one-way ANOVA method. From MTT results, we found that all fractions of papaya were classified as non-toxic to Vero cell with the lower toxicity after treated with chloroform and water fraction. Similar results were found from Vero cell treated with guajava leave fraction with viability above 100%. Based on the Focu Forming Units (FFU) assay, the highest inhibition percentage was n-hexane fraction of papaya leave. The percentage of inhibition of benzene and n hexane guajava leaves fraction were effective as antiviral drug to DENV with the inhibition percentage values of 27.4 % and 33.1%, respectively For the conclusion, the n-hexane fraction of papaya leaves and guajava leaves have potential as DENV antiviral agents in vitro.

Full article